A Deeper Look into PARP Inhibitors in the Management of Ovarian Cancer: Individualizing Treatment for Improved Clinical and Economic Outcomes

A continuing medical education activity provided by NAMCP and AAMCN

New Horizons in the Treatment and Management of Ovarian Cancer: What Managed Care Needs to Know About Recent Advances in PARP Inhibitors is a three-part webinar series

This is Part 2 of the series focusing on individualizing treatment for improved
clinical and economic outcomes in ovarian cancer

This activity is an archive from the webinar held June 17, 2020

This activity is valid from July 1, 2020 to July 1, 2022

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation, and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post-test to receive continuing education credits. If you do not pass the post-test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post-test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
AstraZeneca, GlaxoSmithKline, and Merck Sharp & Dohme Corp.

Description:
There will be an estimated 22,440 new cases of ovarian cancer this year in the United States, and an estimated 14,080 deaths. Ovarian cancer is usually found late, stage 3 or higher, where it has already spread or metastasized to other parts of the abdomen, or worse. The five-year survival rate is only 45%. Fortunately for patients with ovarian cancer, the treatment paradigm has exploded in the past three years, giving HCPs more options in managing patients with ovarian cancer. Leading the way in new options for ovarian cancer are PARP inhibitors, which have shown improved efficacy for patients with ovarian cancer

Upon completion of this activity, participants will be able to:

  • Assess the role of the DNA damage response (DDR) pathway in tumor suppression and describe how mutations in DDR genes lead to tumor proliferation

  • Outline the clinical burden of ovarian cancer and the goals of remission maintenance that can be addressed by clinical pathways

  • Analyze safety and efficacy outcomes from recent clinical data on PARP inhibitors, both in the maintenance setting and in the setting of recurrence following prior use of platinum-based therapy

  • Explore the role of PARP inhibitors as a first-line maintenance therapy for patients with ovarian cancer

  • Examine genetic testing and biomarkers for the identification of patients with ovarian cancer to be treated with PARP inhibition, including those with BRCA-mutated disease

     

Faculty: Kathleen Moore, MD
Virginia Kerley Cade Chair in Developmental Therapeutics
Associate Director, Clinical Research
Director, Oklahoma TSET Phase I Program Stephenson Cancer Center
Associate Professor, Section of Gynecologic Oncology
Director, Gynecologic Oncology Fellowship
Department of Obstetrics and Gynecology
University of Oklahoma Health Sciences Center

Disclosure:

Dr. Moore serves on an advisory board for AstraZeneca, Aravive, Abbvie, Eisai, GSK/Tesaro, Genentech/Roche, Immunogen, Mersana, Merck, VBL Therapeutics, and Tarveda. She has received grant/research support from PTC Therapeutics, Lilly, Merck, and GSK. Her presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
AstraZeneca, GlaxoSmithKline, and Merck Sharp & Dohme Corp.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue